Drugs / cisplatin-e therapeutic implant
cisplatin-e therapeutic implant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00003044 | Sep 1996 → ? | hepatocellular carcinoma | Matrix Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cisplatin-e therapeutic implant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003044 ↗ |
| Known as | Cisplatin/Epinephrine | “IntraDose (Cisplatin/Epinephrine) Injectable Gel (MPI 5010)” NCT00003044 ↗ |
| Known as | IntraDose | “IntraDose (Cisplatin/Epinephrine) Injectable Gel (MPI 5010)” NCT00003044 ↗ |
| Known as | Intradose MPI-5010 | “cisplatin-epinephrine injectable gel (Intradose MPI-5010)” NCT00003044 ↗ |
| Known as | MPI 5010 | “IntraDose (Cisplatin/Epinephrine) Injectable Gel (MPI 5010)” NCT00003044 ↗ |
| Route | Other | “intratumoral treatment” NCT00003044 ↗ |